CPA4: A promising drug target and biomarker for cancer (G51200)

Target Name: CPA4

NCBI ID: G51200

CPA4

CPA4: A promising drug target and biomarker for cancer

Cancer is one of the leading causes of death worldwide, accounting for over 1.8 million deaths in 2020. The development of new treatments is crucial in the fight against cancer. One promising candidate for cancer treatment is CPA4, a protein known as Carboxypeptidase A4 (isoform 1) that has been identified as a potential drug target or biomarker.

CPA4 is a transmembrane protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It is involved in the digestion of peptides, which are large chains of amino acids that are essential for protein synthesis. CPA4 is a potent enzyme that breaks down peptides into smaller chains, which can then be utilized by the body for energy or other essential functions.

CPA4 has also been shown to play a role in the development and progression of various types of cancer. For example, studies have shown that high levels of CPA4 expression are associated with poor prognosis in pancreatic cancer patients. Additionally, CPA4 has been found to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer.

Due to its involvement in the digestion of peptides, CPA4 has also been shown to be a potential drug target for cancer. By inhibiting the activity of CPA4, researchers can potentially slow down or even reverse the growth of cancer cells. This is because when CPA4 is activated, it can break down peptides that are essential for the growth and proliferation of cancer cells.

One approach to inhibiting the activity of CPA4 is through the use of small molecules, such as inhibitors or antagonists. These molecules can be designed to specifically target CPA4 and prevent it from activating and breaking down peptides. Currently, there are several studies being conducted to identify potential inhibitors of CPA4 that can be used as drug targets for cancer.

Another approach to studying CPA4 is through the use of biomarkers. CPA4 is a protein that can be detected in various tissues and fluids, including blood, urine, and tissue samples. By analyzing the levels of CPA4 in these samples, researchers can gain insights into the activity of CPA4 and its potential as a drug target or biomarker.

One of the most promising biomarkers for CPA4 is its ability to be downregulated in response to its activation. This downregulation is caused by the presence of specific RNA molecules, known as microRNAs, which target CPA4 for degradation. By identifying microRNAs that are involved in the downregulation of CPA4, researchers can potentially identify new targets for cancer treatment.

In addition to its potential as a drug target or biomarker, CPA4 is also a promising candidate for cancer diagnosis. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that CPA4 may be a useful diagnostic tool for cancer detection.

Overall, CPA4 is a promising candidate for cancer treatment and diagnosis. Its involvement in the digestion of peptides and its association with various types of cancer make it an attractive target for drug development. Additionally, its ability to be downregulated and its potential as a diagnostic tool make it an exciting area of research for the future.

Protein Name: Carboxypeptidase A4

Functions: Metalloprotease that could be involved in the histone hyperacetylation pathway (PubMed:10383164). Releases a C-terminal amino acid, with preference for -Phe, -Leu, -Ile, -Met, -Tyr and -Val (PubMed:20385563)

The "CPA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets